logo
Neurogenic bladder
Two popular treatment options for neurogenic bladder
Advances in pediatric robotic bladder reconstruction
Relationship between subjective and objective assessments of sacral neuromodulation effectiveness in patients with urgency–frequency
Study suggests that weight loss reduces incontinence in obese women
Novel structure of a subtype of the botulism neurotoxin could be used to enhance therapeutics
Drug adherence is poor in women with urinary trouble
Oxybutynin chloride gel approved by the FDA for overactive bladder treatment
Current and future treatment of neurogenic bladder
Sacral neuromodulation
Neurogenic bladder and urinary diversion
Spinal cord injury and detrusor–sphincter dyssynergia
Application and comparison of the AUA and EAU current recommendations for antibiotic prophylaxis in the urologic patient undergoing office procedures
Anatomy of urinary continence and neurogenic incontinence
Surgical and nonsurgical treatment options for pediatric neurogenic bladder
Botulinum toxin
Regenerative medicine strategies for treatment of neurogenic bladder
Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation
New fears of radiation exposure during cardiac computed tomography angiography
Monitoring BNP levels to guide heart failure therapy gives mixed results
New treatment guidelines for irritable bowel syndrome released
Live Salmonella -based vaccine could fight infant pneumonia
REOLYSIN® enters clinical trial in patients with metastatic colorectal cancer
Liraglutide
Insulin glulisine
Mepolizumab in the treatment of eosinophilic esophagitis
Capecitabine in colorectal cancer
Motor side effects of atypical antipsychotic drugs
Alzheimer's disease
Briefings from ACAAI 2008 Annual meeting
Acknowledgements